Sun Pharma
Search results
Dr. Reddy’s Laboratories, a leading multinational pharmaceutical company based in India and overseas, committed to providing affordable and innovative medicines for healthier lives.
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. [2]
Dr. Reddy’s Laboratories commenced its generics business in India in 1986 and is today a trusted name in the healthcare industry consistently serving the needs of millions of patients with high quality, affordable and innovative medicines across therapy areas.
7 hours ago · Welcome to the Dr. Reddy's Laboratories Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ahead of the market with our in-depth coverage of Dr. Reddy's Laboratories, including: Last traded price 6815.15, Market capitalization: 112618.39, Volume: 61430, Price-to-earnings ratio 20.5, Earnings per share 333.59. Get a complete picture of Dr. Reddy's Laboratories's performance through our comprehensive blend of fundamental and technical ...
22 hours ago · Dr Reddy’s Laboratories announces EMA CHMP approval for Ituxredi, a Rituximab biosimilar for European markets. The approval opens doors for treating non-Hodgkin’s lymphoma, chronic lymphocytic ...
15 hours ago · Dr Reddy’s Laboratories Ltd: The CHMP positive opinion will now be reviewed by the European Commission (EC)as part of the established approval process, and a decision on granting the marketing ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed...
Get the latest Dr Reddy's Laboratories Ltd (DRREDDY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
5 days ago · Dr Reddy's reported better-than-expected Q1 results on July 27. Pharmaceutical major Dr Reddy's Laboratories targets double-digit revenue growth from its India business through FY25. This growth ...
Dr. Reddy’s Laboratories announced a 1:5 stock split and plans a GBP 500 million investment in its Swiss subsidiary for acquiring Nicotinell and related brands. The company's June quarter profit ...
